FDA Warning Letter
Zealthy — FDA Warning Letter (September 9, 2025)
Legal name: FitRX, LLC
In plain English
Online sale of unapproved drugsFDA said Zealthy offered semaglutide products to U.S. consumers online that the agency considers unapproved and misbranded drugs.
What it means for you
Drugs sold this way have not been reviewed by FDA for safety, quality, or effectiveness. Fill a GLP-1 prescription only through a state-licensed pharmacy.
Primary Source
View the original FDA letter on fda.gov →
https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fitrx-llc-dba-zealthy-716501-09092025
Letter details
- Company
- FitRX, LLC (dba Zealthy)
- Letter number
- Not given by FDA
- Issue date
- September 9, 2025
- Subject
- Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet
What FDA warning letters mean
A warning letter is FDA's principal means of telling a company that the agency considers something it's doing — a marketing claim, a manufacturing practice, a labeling choice — to violate the Federal Food, Drug, and Cosmetic Act. Companies typically have 15 working days to respond.
A warning letter is not a recall, a criminal charge, or a finding that the company has broken the law. It is the start of a regulatory conversation. FDA may issue a close-out letter once it is satisfied that the company has corrected the cited issues.
For compounded GLP-1 telehealth providers, the most common citations involve unapproved new drug claims, misbranding, and the use of bulk drug substances not on FDA's approved list under FDCA sections 503A and 503B.
What this letter means if you use compounded GLP-1s
A warning letter is not a recall, and it does not by itself mean a product you already have is unsafe, but it does mean the FDA found problems it expects Zealthy to fix. Compounded GLP-1s are not FDA-approved, and the rules for selling them changed when the shortages ended; our explainer on where compounded semaglutide stands with the FDA now covers what is still allowed.
This letter concerns drugs offered for sale online, so the first check is whether a seller is a licensed pharmacy at all. Our guide to spotting counterfeit semaglutide covers the warning signs, and the semaglutide page lists the FDA-approved brands.
Other warning letters in our database
- Chengdu Brilliant Biopharmaceutical Co., Ltd. — September 11, 2025
- Motionpharmacycom — September 10, 2025
- Try Nova MD — September 9, 2025
- SemaBio — September 9, 2025
- Novo Nordisk Inc. — September 9, 2025
Editorial Disclaimer
FDA warning letters are public regulatory communications and do not, on their own, indicate that a company has done anything illegal. Companies often respond to warning letters with corrective action, and many letters are eventually closed out. The full text of this letter is available on fda.gov via the link above.
Key terms, explained
New to GLP-1s? Tap any term for a quick, plain-English definition.
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- 503B outsourcing facility · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- FDA Warning Letter · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory